The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Plasma Proteins Market Research Report 2025
Synopsis
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
The global Recombinant Plasma Proteins market was valued at US$ 92 million in 2023 and is anticipated to reach US$ 106.4 million by 2030, witnessing a CAGR of 2.1% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Recombinant Plasma Proteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Plasma Proteins.
Report Scope
The Recombinant Plasma Proteins market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Plasma Proteins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Plasma Proteins companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Plasma Proteins companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
The global Recombinant Plasma Proteins market was valued at US$ 92 million in 2023 and is anticipated to reach US$ 106.4 million by 2030, witnessing a CAGR of 2.1% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Recombinant Plasma Proteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Plasma Proteins.
Report Scope
The Recombinant Plasma Proteins market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Plasma Proteins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Plasma Proteins companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Plasma Proteins companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Plasma Proteins Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chinese Hamster Ovary (CHO) Cell Line
1.2.3 Baby Hamster Kidney (BHK) Cell Line
1.2.4 Human Embryonic Kidney (HEK) Cell Line
1.2.5 Others
1.3 Market by Application
1.3.1 Global Recombinant Plasma Proteins Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hemophilia A
1.3.3 Hemophilia B
1.3.4 Von Willebrand Disease
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Plasma Proteins Market Perspective (2019-2030)
2.2 Recombinant Plasma Proteins Growth Trends by Region
2.2.1 Global Recombinant Plasma Proteins Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Plasma Proteins Historic Market Size by Region (2019-2024)
2.2.3 Recombinant Plasma Proteins Forecasted Market Size by Region (2025-2030)
2.3 Recombinant Plasma Proteins Market Dynamics
2.3.1 Recombinant Plasma Proteins Industry Trends
2.3.2 Recombinant Plasma Proteins Market Drivers
2.3.3 Recombinant Plasma Proteins Market Challenges
2.3.4 Recombinant Plasma Proteins Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Plasma Proteins Players by Revenue
3.1.1 Global Top Recombinant Plasma Proteins Players by Revenue (2019-2024)
3.1.2 Global Recombinant Plasma Proteins Revenue Market Share by Players (2019-2024)
3.2 Global Recombinant Plasma Proteins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Plasma Proteins Revenue
3.4 Global Recombinant Plasma Proteins Market Concentration Ratio
3.4.1 Global Recombinant Plasma Proteins Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Plasma Proteins Revenue in 2023
3.5 Recombinant Plasma Proteins Key Players Head office and Area Served
3.6 Key Players Recombinant Plasma Proteins Product Solution and Service
3.7 Date of Enter into Recombinant Plasma Proteins Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Plasma Proteins Breakdown Data by Type
4.1 Global Recombinant Plasma Proteins Historic Market Size by Type (2019-2024)
4.2 Global Recombinant Plasma Proteins Forecasted Market Size by Type (2025-2030)
5 Recombinant Plasma Proteins Breakdown Data by Application
5.1 Global Recombinant Plasma Proteins Historic Market Size by Application (2019-2024)
5.2 Global Recombinant Plasma Proteins Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Plasma Proteins Market Size (2019-2030)
6.2 North America Recombinant Plasma Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant Plasma Proteins Market Size by Country (2019-2024)
6.4 North America Recombinant Plasma Proteins Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Plasma Proteins Market Size (2019-2030)
7.2 Europe Recombinant Plasma Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant Plasma Proteins Market Size by Country (2019-2024)
7.4 Europe Recombinant Plasma Proteins Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Plasma Proteins Market Size (2019-2030)
8.2 Asia-Pacific Recombinant Plasma Proteins Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Plasma Proteins Market Size (2019-2030)
9.2 Latin America Recombinant Plasma Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant Plasma Proteins Market Size by Country (2019-2024)
9.4 Latin America Recombinant Plasma Proteins Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Plasma Proteins Market Size (2019-2030)
10.2 Middle East & Africa Recombinant Plasma Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CSL Limited
11.1.1 CSL Limited Company Detail
11.1.2 CSL Limited Business Overview
11.1.3 CSL Limited Recombinant Plasma Proteins Introduction
11.1.4 CSL Limited Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.1.5 CSL Limited Recent Development
11.2 Shire (Takeda Pharmaceutical Company Limited)
11.2.1 Shire (Takeda Pharmaceutical Company Limited) Company Detail
11.2.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Introduction
11.2.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.3 Octapharma
11.3.1 Octapharma Company Detail
11.3.2 Octapharma Business Overview
11.3.3 Octapharma Recombinant Plasma Proteins Introduction
11.3.4 Octapharma Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.3.5 Octapharma Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Recombinant Plasma Proteins Introduction
11.4.4 Novo Nordisk Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.4.5 Novo Nordisk Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Recombinant Plasma Proteins Introduction
11.5.4 Bayer Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.5.5 Bayer Recent Development
11.6 Bioverativ Therapeutics, Inc. (Sanofi)
11.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Company Detail
11.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Business Overview
11.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Introduction
11.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Development
11.7 Aptevo Therapeutics
11.7.1 Aptevo Therapeutics Company Detail
11.7.2 Aptevo Therapeutics Business Overview
11.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Introduction
11.7.4 Aptevo Therapeutics Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.7.5 Aptevo Therapeutics Recent Development
11.8 Pharming Group
11.8.1 Pharming Group Company Detail
11.8.2 Pharming Group Business Overview
11.8.3 Pharming Group Recombinant Plasma Proteins Introduction
11.8.4 Pharming Group Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.8.5 Pharming Group Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Recombinant Plasma Proteins Introduction
11.9.4 Pfizer Revenue in Recombinant Plasma Proteins Business (2019-2024)
11.9.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
